A study by Lee et al. utilizing PDX mouse models inoculated with human tumor cells found that CD44+ cells expressed higher levels of EMT markers and Programmed death-ligand 1 (PD-L1) compared to CD44− cells (Lee et al., 2016). This evidence concerns the gene CD44 and neoplasm.